Holen Sie sich die Stockscreener-App
34.47
0.19%
0.065
Schlusskurs vom Vortag:
$34.40
Offen:
$34.47
24-Stunden-Volumen:
362.99K
Relative Volume:
0.81
Marktkapitalisierung:
$955.06M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-11.30
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+1.97%
1M Leistung:
+21.91%
6M Leistung:
+322.37%
1J Leistung:
+316.24%
1-Tages-Spanne:
$33.90
$35.72
1-Wochen-Bereich:
$30.00
$35.72
52-Wochen-Spanne:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
34.47 | 955.19M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-26 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Can RAPT Therapeutics Inc. (0RA) stock deliver strong annual returnsMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-04 13:14:54 - Newser
How RAPT Therapeutics Inc. (0RA) stock compares with tech leadersPortfolio Return Summary & Reliable Volume Spike Alerts - Newser
How robust is RAPT Therapeutics Inc. (0RA) stock financial positionVolume Spike & Risk Managed Trade Strategies - Newser
Does RAPT Therapeutics Inc (RAPT) offer a good opportunity for investors? - Setenews
Can RAPT Therapeutics Inc. (0RA0) stock sustain margin levels2025 Biggest Moves & Fast Moving Market Watchlists - Newser
What macro factors could drive RAPT Therapeutics Inc. (0RA0) stock higherRecession Risk & Fast Exit/Entry Strategy Plans - Newser
Why RAPT Therapeutics Inc. (0RA) stock is trending on social mediaFed Meeting & Safe Capital Allocation Plans - Newser
How RAPT Therapeutics Inc. (0RA0) stock performs in easing cyclesRisk Management & Technical Pattern Based Buy Signals - Newser
Published on: 2025-12-02 05:12:24 - Newser
Can RAPT Therapeutics Inc. (0RA) stock ride next bull market cycle2025 Big Picture & Growth Oriented Trade Recommendations - Newser
RAPT Therapeutics announces planned departure of chief medical officer By Investing.com - Investing.com Nigeria
RAPT Therapeutics announces planned departure of chief medical officer - Investing.com
RAPT Therapeutics Announces CMO Departure - TipRanks
RAPT Therapeutics Announces Departure of Chief Medical Officer - TradingView
Are Smart Investors Making the Right Decision? RAPT Therapeutics Inc (RAPT) - Setenews
RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Market Cap Touched US$830m Last Week, Benefiting Both Individual Investors Who Own 34% as Well as Institutions - 富途牛牛
While institutions invested in RAPT Therapeutics, Inc. (NASDAQ:RAPT) benefited from last week's 17% gain, individual investors stood to gain the most - simplywall.st
Form 8-KCurrent report - ADVFN
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position - MSN
RAPT Therapeutics Shares Surge on Institutional Confidence and Clinical Progress - AD HOC NEWS
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
Will RAPT Therapeutics Inc. stock outperform Nasdaq index2025 Market Overview & Fast Moving Market Watchlists - newser.com
Why RAPT Therapeutics Inc. stock appeals to dividend seekersWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Why analysts remain bullish on RAPT Therapeutics Inc. stockTrade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Can RAPT Therapeutics Inc. stock deliver sustainable ROE2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
D pipelineJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Is RAPT Therapeutics Inc. (0RA) stock a good hedge against inflationRisk Management & Daily Risk Controlled Trade Plans - newser.com
How strong is RAPT Therapeutics Inc. stock revenue growthWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Is RAPT Therapeutics Inc. stock a buy before product launches2025 Biggest Moves & Long-Term Investment Growth Plans - newser.com
How supply shortages influence RAPT Therapeutics Inc. (0RA0) stockJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
How RAPT Therapeutics Inc. (0RA0) stock stacks up against competitorsJuly 2025 Selloffs & Risk Controlled Daily Plans - newser.com
Published on: 2025-11-19 17:30:40 - newser.com
Can RAPT Therapeutics Inc. recover in the next quarter2025 Trading Volume Trends & Stock Timing and Entry Methods - newser.com
Is RAPT Therapeutics Inc. (0RA) stock dividend growth reliable2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Published on: 2025-11-19 14:44:45 - newser.com
Is RAPT Therapeutics Inc. stock reversal real or fakePortfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com
What institutional flow reveals about RAPT Therapeutics Inc.Trade Volume Report & Weekly Market Pulse Updates - newser.com
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):